Speaker Profile

Vice President of Business Development, MMRF

Christopher Williams was named Vice President of Business Development at the MMRF in 2017, responsible for business development, partnership and joint venture efforts for the foundation. He is a business development leader with a strong scientific background, specializing in the pharmaceutical and diagnostics space. Most recently he served as the VP of Business Development at WaveSense where he was in charge of their US commercialization strategy and product expansion, as well as being responsible for overseeing their strategic partner relationships. Previously Chris was VP of Business Development at SkylineDx, providing commercialization strategy for their oncology portfolio. With PerkinElmer, as the Market Segment Leader in Oncology, he had responsibility for their cancer diagnostic products including strategy, launch activities, external presentations and marketing execution. While at Millennium Pharmaceuticals, Chris held roles in the Protein Science, Technology Development and Proteomics groups. He also had scientific roles at Schering-Plough and the Sandoz Research Institute. Chris holds graduate and post-graduate degrees in Microbiology/Molecular Biology and Protein Biochemistry from Clemson University.

AI and Data Sciences Showcase:

A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for every multiple myeloma patient by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer.

Innovation Of Patient-Centered Research Initiatives: MMRF CureCloud
The first-of-its-kind, innovative MMRF CureCloud research study features direct-to-patient enrollment, the first at-home CLIA-grade cfDNA sequencing test for myeloma, and real-world EHR data collection to deliver real-time insights back to patients and their physicians to inform clinical decision-making.

 Session Abstract – PMWC 2022 Silicon Valley

Track 7, June 28-30

The PMWC 2022 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.